What is ARTMS?
ARTMS specializes in the development and supply of QUANTM irradiation systems, which empower local cyclotrons to generate essential medical isotopes on-site. By enabling the production of isotopes such as Gallium-68 directly at the point of care, the company mitigates the risks associated with long-distance transport and decay-related supply shortages. This innovative approach not only enhances the operational efficiency of existing cyclotron facilities but also expands the accessibility of advanced diagnostic imaging for patients worldwide. Through strategic collaborations with drug innovators and medical distributors, ARTMS is positioning itself as a critical node in the modern healthcare supply chain, driving advancements in precision medicine and diagnostic accuracy.
How much funding has ARTMS raised?
ARTMS has raised a total of $22M across 2 funding rounds:
Private Equity
$3M
Series A
$19M
Private Equity (2017): $3M with participation from Quark Venture Inc. and GF Securities
Series A (2020): $19M led by Deerfield Communications Inc, GF Securities Co. Ltd, and Quark Venture
Key Investors in ARTMS
Quark Venture
Quark Venture LP is a venture capital firm specializing in equity financing for innovative biotechnology companies with breakthrough technology platforms.
GF Securities
A prominent financial services provider offering comprehensive investment banking and asset management services with a focus on high-growth industrial sectors.
Deerfield Communications Inc
An investment entity participating in the strategic financing of healthcare and technology-driven enterprises.
What's next for ARTMS?
With the support of its recent major enterprise-level funding, ARTMS is well-positioned to scale its manufacturing footprint and accelerate the integration of its technology into global clinical networks. The strategic focus will likely shift toward expanding the portfolio of isotopes compatible with the QUANTM platform, thereby broadening the company's reach into new therapeutic areas. As the demand for personalized medicine continues to rise, ARTMS is poised to leverage its capital reserves to solidify its leadership in the nuclear medicine sector, potentially exploring further partnerships with pharmaceutical entities to streamline the delivery of radiopharmaceuticals. The company's ability to maintain its technological edge while scaling operations will be the primary determinant of its long-term market dominance.
See full ARTMS company page
